What you’ll learn on this page:
- Infilbray demonstrated a reduction in GL-1 and lyso-GL-1 in the CNS1
Infilbray was shown to cross the blood-brain barrier and reduce GL-1 and lyso-GL-1 accumulation in the CSF1
Crosses the blood-brain barrier1
Infilbray can access the brain, enabling it to provide activity in the CNS.1,2
Reduces toxic accumulation of GL-1 and lyso-GL-11
Infilbray is a glucosylceramide synthase inhibitor (GCSi) that reduces the synthesis of GL-1 and subsequently lyso-GL-1.1,3
Pharmacodynamic data were taken from the clinical study of adult and pediatric patients 12 years of age and older with Gaucher disease type 3 who had received ERT and were clinically stable for at least one year in terms of hemoglobin, platelet count, liver volume, and spleen volume. Patients in the Infilbray arm received either 12 mg or 15 mg doses once per day, depending on weight and age. Patients in the imiglucerase arm received imiglucerase intravenously every two weeks. The primary endpoint of the study was the O'Brien OLS global test of multiple endpoints including the 4-item SARA and RBANS total scale index score.1
Demonstrated reduction from baseline of neurologic GL-1 and lyso-GL-1 in adults at Week 521,4
LS mean changes in CSF GL-1

LS mean changes in CSF lyso-GL-1

Infilbray patients showed reductions in GL-1 and lyso-GL-1 in CSF of 64% (SE=8%) and 58% (SE=10%) from baseline, respectively.1
Frequently asked questions
Definitions: CNS=central nervous system; CSF=cerebrospinal fluid; ERT=enzyme replacement therapy; GCS=glucosylceramide synthase; GL-1=glucosylceramide; LS=least squares; lyso-GL-1=glucosylsphingosine; OLS=ordinary least squares test; RBANS=Repeatable Battery for the Assessment of Neuropsychological Status; SARA=Scale for the Assessment and Rating of Ataxia; SE=standard error.
Relevant pages to view:
Indication
References: 1. Infilbray (venglustat). Prescribing information. Genzyme Corporation, Cambridge, MA. 2. Schiffmann R et al. J Inherit Metab Dis. 2020;43(5):1056-1059. 3. Grabowski GA et al. The Online Metabolic and Molecular Bases of Inherited Disease. Accessed August 4, 2026. https://ommbid.mhmedical.com/content.aspx?bookid=2709§ionid=225546056 4. Mistry P et al. Poster presented at: WORLDSymposium; February 2-6, 2026; San Diego, CA. 5. Boddupalli CS et al. eLife. 2022;11:e79830. doi:10.7554/eLife.79830
